Co-led by Mubadala Capital and Horizons Ventures, funding will power Juvena’s artificial intelligence-enabled drug discovery platform to map the therapeutic potential of secreted proteins REDWOOD CITY, Calif.–(BUSINESS WIRE)–Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today that it has raised $41 million in … [Read more…]

MAHWAH, N.J.–(BUSINESS WIRE)–KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced the progression of its agreement with Kira Pharmaceuticals, including expansion into three important additional indications. Kira will utilize KORU Medical’s Freedom System for Phase … [Read more…]

The Phase II multi-center, open label trial will evaluate BT8009 administered at the recommended Phase II doses of 5mg/m2 and 7.5mg/m2 Phase I dose escalation cohorts complete; results to be presented at a medical conference in 1H 2023 Confirmed RECIST response in a non-small cell lung cancer patient CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc … [Read more…]

– Allogeneic CAR T Program Updates Planned for Late Q4 2022 or Early Q1 2023 – Abstract Showcasing Functional Attributes of Azer-cel (PBCAR1091) Accepted for Presentation at the 64th American Society of Hematology (ASH) Annual Meeting – Preclinical Research on In Vivo Gene Editing Programs Presented at the European Society of Gene & Cell Therapy … [Read more…]

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $21.3 million in the third quarter of 2022 (+23% vs. 2Q 2022) Cash runway expected into early 2025 Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the third quarter ended September 30, 2022 and provided … [Read more…]

Study demonstrated minimal-to-no systemic exposure despite maximal use Subjects were as young as 2 years old with up to 90% body surface area (BSA) affected and a mean BSA of 43% Maximal usage study utilized same dose of VTAMA cream, 1% currently FDA-approved for adult plaque psoriasis LONG BEACH, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Dermavant Sciences, … [Read more…]

Preclinical data support the clinical potential of Turnstone’s next-generation Selected TIL therapy to improve TIL efficacy against solid tumor malignancies Presentations highlight novel method to select the most potent tumor-reactive T-cells (Selected TILs) with the potential to overcome the limitations of conventional TIL-based therapies SAN DIEGO–(BUSINESS WIRE)–#SITC2022–Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation … [Read more…]

NEW YORK & LONDON & PARIS–(BUSINESS WIRE)–Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold its 2022 annual general meeting of shareholders at its London office … [Read more…]

Third quarter revenue of $712 million; (17)% reported growth Pro forma* total revenue of $1,033 million; 9% pro forma non-COVID organic growth Third quarter GAAP EPS from continuing operations of $0.55; pro forma adjusted EPS of $1.51 Initiates fourth quarter and updates full year pro forma guidance WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE: PKI), a global … [Read more…]

FLOWER MOUND, Texas–(BUSINESS WIRE)–Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2022. Third Quarter End Results Third quarter net sales for 2022 were $35.5 million, a decrease of $3.9 million, or 10.0%, as compared to … [Read more…]